Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of fixed-dose subcutaneous reslizumab in severe eosinophilic asthma
MOH_2017-04-05_000308Phase 3Not yet recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of reslizumab in eosinophilic asthma (EA) and asthma, sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Long-term safety of subcutaneous reslizumab. Planned start Feb 2017; status: not yet recruiting.
02
Drugs
reslizumab
03
Conditions
eosinophilic asthma (EA)asthma
Beyond the preview
Go deeper on MOH_2017-04-05_000308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-05_000308.